Kathie M. Bishop

Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy

Richard S. Finkel, Eugenio Mercuri, Basil T. Darras et al. · New England Journal of Medicine · 2017 · 2.3K citations · Full text

Medicine, Genetics, Neurology +17

Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy

Eugenio Mercuri, Basil T. Darras, Claudia A. Chiriboga et al. · New England Journal of Medicine · 2018 · 1.4K citations · Full text

Medicine, Neurology, Neuroscience +17

Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study

Richard S. Finkel, Claudia A. Chiriboga, Jiri Vajsar et al. · The Lancet · 2016 · 1K citations

Medicine, Neurology, Neuromuscular Disorders +9

An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study

Timothy M. Miller, Alan Pestronk, William David et al. · The Lancet Neurology · 2013 · 607 citations · Full text

Medicine, Neurology, Pharmacology +17

Results from a phase 1 study of nusinersen (ISIS-SMN _Rx ) in children with spinal muscular atrophy

Claudia A. Chiriboga, Kathryn J. Swoboda, Basil T. Darras et al. · Neurology · 2016 · 602 citations · Full text

Medicine, Neurology, Pharmacology +14